종근당

185750KOSPI

57.0 / 100

Reference Date: 2026-10-23

Financial Score27.5 / 40

News Sentiment12.5 / 25

Momentum7.0 / 20

Disclosure10.0 / 15

AI Analysis: the debt ratio is very low with excellent financial health but Operating Profit is on a declining trend. Slightly down 1.2% over the past month, with no recent news.

Company InformationBased on 2025 Annual Report

Business Overview

Jonggun Pharm is a major South Korean pharmaceutical company established in 1941, specializing in both prescription and over-the-counter drugs. It invests 9-11% of its sales in R&D, focusing on new drug development and biosimilars, with key products including the anticancer drug 'Camtovel' and the diabetes treatment 'Duvie'. As of 2023, it holds approximately 5% of the domestic pharmaceutical market share.

Number of Employees

2,304people

Average Salary

79.6M KRW

Score Calculation Basis

Detailed Financial Score

PER

11.02Industry Average 15.006.5Point

Lower than industry avg (good)

PBR

0.89Industry Average 1.205.5Point

Lower than industry avg (good)

ROE

8.18Industry Average 8.004.0Point

In line with industry avg

Debt Ratio

27.61Industry Average 100.008.0Point

Half of industry avg (excellent)

Trend 2023~20253.5 / 10 points

Revenue Growth Rate

1.0 / 3

Avg ▲0.9% (2-year basis)

Operating Profit Growth Rate

0.0 / 3

Avg ▼39.3% (2-year basis)

ROE Trend

2.5 / 4

Avg ROE 17.0% (declining, 3yr)

Detailed News Sentiment

0 totalPositive 0Neutral 0Negative 0

Detailed Momentum

52-week position1.0Point

Near 52w low (2%, downtrend)

Current 64,800Won52-week high 97,70052-week low 64,100

1-month return3.0Point

1m -1.22% (flat)

Volume trend3.0Point

Volume flat

Detailed Disclosure

9 totalPositive 0Neutral 9Negative 0

Neutral[기재정정]반기보고서 (2026.06)2026-10-22
Neutral[기재정정]반기보고서 (2026.06)2026-10-22
Neutral[기재정정]반기보고서 (2026.06)2026-10-22
Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-10-08
Neutral주식등의대량보유상황보고서(일반)2026-10-08